Read by QxMD icon Read


AmirReza Hesari, Faezeh Ghasemi, Reza Salarinia, Hamed Biglari, Agheel Tabar Molla Hassan, Vali Abdoli, Hamed Mirzaei
Curcumin is a yellow-orange powder derived from the Curcuma longa plant. Curcumin has been used extensively in traditional medicine for centuries. This component is non-toxic and shown different therapeutic properties such as anti-inflammatory, anti-cancer, antiviral, anti-bacterial, anti-fungal, anti-parasites, and anti-oxidant. Hepatitis B virus (HBV) is a small DNA member of the genus Orthohepadnavirus (Hepadnaviridae family) which is a highly contagious blood-borne viral pathogen. HBV infection is a major public health problem with 2 billion people infected throughout the world and 350 million suffering from chronic HBV infection...
June 19, 2018: Journal of Cellular Biochemistry
Mona Seyed Attaran, Seyed Masoud Hosseini, Javad Fakhari, Zohreh Sharifi
Background and Objectives: Hepatitis B virus (HBV) is an enveloped DNA virus belongs to Hepadnaviridea family. HBV infection is a serious global health problem, with 2 billion people infected worldwide, and 350 million suffering from chronic HBV infection. The aim of this study was to determine the serological pattern and molecular characterization of HBV diversity in asymptomatic blood donors in Iran alongside with the mutation status of HBV in relation to blood safety. Materials and Methods: One hundred and sixty six samples from asymptomatic blood donors who were positive for hepatitis B surface antigen during 2012 to 2014 were selected...
February 2018: Iranian Journal of Microbiology
Hiroteru Kamimura, Toru Setsu, Naruhiro Kimura, Takeshi Yokoo, Akira Sakamaki, Kenya Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Satoshi Yamagiwa, Shuji Terai
The liver plays a key role in the metabolism of proteins. Liver dysfunction affects many organs because it communicates with the spleen and all digestive organs through the portal vein. Additionally, the kidney is an organ that is closely related to the liver and is involved in liver diseases. Glomerulonephritis is an important extrahepatic manifestation of chronic hepatitis B virus (HBV) infection. Nucleos(t)ide analog (NA) therapy effectively suppresses HBV replication by inhibiting HBV polymerase, thus decreasing the levels of serum HBV-DNA and delaying the progression of cirrhosis...
June 19, 2018: Diseases (Basel)
A Loglio, M Iavarone, G Grossi, M Viganò, M G Rumi, F Facchetti, G Lunghi, A Sangiovanni, M Colombo, P Lampertico
BACKGROUND: Long-term oral nucleos(t)ide analogue (NUC) therapy in hepatitis B virus (HBV)-related compensated cirrhotics prevents clinical decompensation but not hepatocellular carcinoma (HCC) development. AIMS: To define the clinical features and outcomes of HCC in long-term NUC-treated HBV patients. METHODS: All HCCs developing between 2005 and 2016 in NUC-treated HBV patients under surveillance were studied, excluding those that occurred within the first 6 months of therapy...
June 19, 2018: Alimentary Pharmacology & Therapeutics
Babak Sayad, Yosra Naderi, Seyed Moayed Alavian, Farid Najafi, Alireza Janbakhsh, Feyzollah Mansouri, Siavash Vaziri, Mandana Afsharian, Fatemeh Norooznezhad
Aim: This study aimed to determine the seroprevalence and viremic infection of hepatitis delta virus (HDV) in Kermanshah. Background: Hepatitis delta is one of the most complex viral infections of liver that along with hepatitis B virus could lead to fulminant hepatitis, progressive chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Methods: Referrals with positive HBs Ag were included and tested for HDV Ab using ELISA. Seropositives were subsequently evaluated for viremia by assaying HDV RNA and HBV DNA using real-time PCR...
2018: Gastroenterology and Hepatology From Bed to Bench
Xinglong Chen, Xiuqiong Zhang, Yunbao Ma, Zhentao Deng, Changan Geng, Jijun Chen
Five new iridal-type triterpenoids, named as spirioiridoconfal A-C (1-3), isobelamcandal (4) and 17-hydroxyl-27-ene-iridal (5), along with one known compound (6) were isolated from the whole plant of Iris confusa. Their structures were determined by extensive spectroscopic analyses. Compounds 3 and 6 showed moderate activity against HBV DNA replication in vitro with the IC50 value at 84.6 ± 24.9 (SI = 2.1) and 58.6 ± 6.1 (SI = 12.7) μM relatively.
June 12, 2018: Fitoterapia
Koen Vandyck, Geert Rombouts, Bart Stoops, Abdellah Tahri, Ann Vos, Wim Verschueren, Yiming Wu, Jingmei Yang, Fuliang Hou, Bing Huang, Karen Vergauwen, Pascale Dehertogh, Jan-Martin Berke, Pierre Jean Marie Bernard Raboisson
Small molecule induced Hepatitis B virus (HBV) capsid assembly modulation is considered an attractive approach for new antiviral therapies against HBV. Here we describe efforts towards the discovery of a HBV capsid assembly modulator in a hit-to-lead optimization, resulting in JNJ-632, a tool compound used to further profile the mode of action. Administration of JNJ-632 (54) in HBV genotype D infected chimeric mice, resulted in a 2.77 log reduction of the HBV DNA viral load.
June 15, 2018: Journal of Medicinal Chemistry
Heng Chi, Zhandong Li, Bettina E Hansen, Tao Yu, Xiaoyong Zhang, Jian Sun, Jinlin Hou, Harry L A Janssen, Jie Peng
BACKGROUND & AIMS: Levels of antibodies against the hepatitis B virus (HBV) core protein (anti-HBc) have been associated with response to nucleos(t)ide analogue and (peg)interferon therapy in patients with chronic HBV infection. We performed a prospective study to determine whether the total serum level of anti-HBc level (immunoglobulins M and G) is associated with clinical relapse after discontinuation of nucleos(t)ide analogue-based therapy. METHODS: We collected data from patients with chronic HBV infection who discontinued nucleos(t)ide analogue therapy according to pre-specified stopping criteria, recruited from November 2012 through July 2016 at an academic hospital in Guangzhou, China...
June 11, 2018: Clinical Gastroenterology and Hepatology
Hwi Young Kim, Jeong-Ju Yoo, Sohee Oh, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Won Kim, Yong Jin Jung, Bo Hyun Kim, Chang-Min Kim, Joong-Won Park, Jeong-Hoon Lee
Prophylactic antiviral therapy is recommended for hepatitis B virus (HBV)-infected patients with malignancies who are undergoing systemic chemotherapy. In the present study, we aimed to develop a risk scoring system to guide the selection of prophylactic antiviral agents. In this retrospective analysis, we included consecutive chronic hepatitis B patients who received antiviral prophylaxis for chemotherapy of solid or hematologic malignancies at 3 large-volume hospitals in Korea. The primary endpoint was HBV reactivation...
June 13, 2018: Journal of Medical Virology
Di Zhao, Xuemei Jiang, Yong Xu, Huimin Yang, Dongni Gao, Xueen Li, Lifen Gao, Chunhong Ma, Xiaohong Liang
Siglec-9 is an MHC-independent inhibitory receptor selectively expressed on CD56dim NK cells. Its role in infection diseases has not been investigated yet. Here, we studied the potential regulatory roles of NK Siglec-9 in the pathogenesis of chronic hepatitis B (CHB) infection. Flow cytometry evaluated the expression of Siglec-9 and other receptors on peripheral NK cells. Immunofluorescence staining was used to detect Siglec-9 ligands on liver biopsy tissues and cultured hepatocyte cell lines. Siglec-9 blocking assay was carried out and cytokine synthesis and CD107a degranulation was detected by flow cytometry...
2018: Frontiers in Immunology
Norio Akuta, Fumitaka Suzuki, Mariko Kobayashi, Tetsuya Hosaka, Shunichiro Fujiyama, Yusuke Kawamura, Hitomi Sezaki, Masahiro Kobayashi, Satoshi Saitoh, Yoshiyuki Suzuki, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada
It is currently unclear what impact serum microRNA-122 (miR-122) levels have on clearance of hepatitis B virus (HBV) surface antigen (HBsAg) in HBV-infected patients who had not received antiviral therapy. The present study evaluated the impact of serum miR-122 levels on HBsAg seroclearance in 367 consecutive HBV-infected patients who had not received antiviral therapy between their initial and last visit, and investigated the predictive factors of HBsAg seroclearance. Cumulative HBsAg seroclearance rates were 13...
June 13, 2018: Journal of Medical Virology
Sonia Roman
Occult hepatitis B infection (OBI) is the presence of hepatitis B virus (HBV) DNA in the liver and/or serum (< 200 IU/mL) in HBsAgnegative patients with or without serologic markers of previous viral exposure. The clinical significance of OBI is of concern in posttransfusional hepatitis B infection, hepatitis B reactivation, chronic liver disease and hepatocellular carcinoma (HCC). The diagnosis of OBI relays on the use of highly sensitive and specific laboratory techniques. Herein, comments derived from a study analyzing the frequency and characteristics of OBI in HCC Japanese patients are stated...
June 20, 2018: Annals of Hepatology
Christoph Höner Zu Siederdissen, Aric Josun Hui, Wattana Sukeepaisarnjaroen, Pisit Tangkijvanich, Wei Wen Su, Gerardo Enrique Guillén Nieto, Paul Gineste, Josianne Nitcheu, Sandrine Crabé, Sandrine Stepien, Michael P Manns, Christian Trépo, Heiner Wedemeyer, Markus Cornberg
Stopping long-term nucleos(t)ide analogue therapy increases HBsAg loss rates in HBeAg-negative patients. Viral rebound may induce immune responses facilitating functional cure. We analyzed which factors are associated with timing of virological relapse in 220 Asian HBeAg-negative patients from the prospective ABX203 vaccine study. Unexpectedly, only the type of antiviral therapy was significantly associated with early virological relapse, defined as HBV DNA > 2,000 IU/ml until week 12 and occurred earlier in patients treated with tenofovir versus entecavir (median time 6 versus 24 weeks, p < 0...
June 9, 2018: Journal of Infectious Diseases
Jun Muto, Masaya Sugiyama, Ken Shirabe, Motokazu Mukaide, Ikue Kirikae-Muto, Toru Ikegami, Tomoharu Yoshizumi, Yo-Ichi Yamashita, Yoshihiko Maehara, Masashi Mizokami
INTRODUCTION AND AIM: Occult hepatitis B virus (HBV) infection (OBI) represents a state without detectable hepatitis B surface antigen, but positive for HBV DNA. The correlation between OBI and hepatocellular carcinoma (HCC) carcinogenesis is controversial. We studied the frequency and characteristics of OBI among HCC patients and metastatic liver cancer patients. MATERIAL AND METHODS: DNA was obtained from tumor and non-tumor tissues from 75 HCC patients (15 chronic hepatitis B (CHB), 39 chronic hepatitis C (CHC), 21 cryptogenic) and 15 metastatic liver cancer patients who underwent liver resection...
July 2018: Annals of Hepatology
Jin Hu, Junjun Cheng, Liudi Tang, Zhanying Hu, Yue Luo, Yu-Huan Li, Tianlun Zhou, Jinhong Chang, Ju-Tao Guo
Hepatitis B virus (HBV) has infected one-third of world population and 240 million people are chronic carriers, to whom a curative therapy is still not available. Similar to other viruses, persistent HBV infection relies on the virus to exploit host cell functions to support its replication and efficiently evade host innate and adaptive antiviral immunity. Understanding HBV replication and concomitant host cell interactions is thus instrumental for development of therapeutics to disrupt the virus-host interactions critical for its persistence and cure chronic hepatitis B...
June 12, 2018: ACS Infectious Diseases
Sanae Hayashi, Anis Khan, Brenna C Simons, Chriss Homan, Takeshi Matsui, Kenji Ogawa, Keigo Kawashima, Shuko Murakami, Satoru Takahashi, Masanori Isogawa, Kazuho Ikeo, Masashi Mizokami, Brian J McMahon, Yasuhito Tanaka
Hepatitis B virus (HBV) genotype F1b infection is strongly associated with hepatocellular carcinoma (HCC) in young Alaskan Native (AN) people. However, the mechanisms by which genotype F1b causes HCC are unclear. Here, we analyzed the clinical and virological significance of genotype F1b in long-term serial samples from 20 HCC patients with HBV infection. Complete sequence analyses revealed that all isolates were genotype F1b. In the HCC patients, T1938C and A2051C mutations in the core region had accumulated significantly with A1762T/G1764A mutations in the basal core promoter (BCP) region and G1896A mutation in the precore (PC) region...
June 12, 2018: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
J Lee, M Y Kim, S H Kang, J Kim, Y Uh, K J Yoon, H S Kim
Objective Noninvasive liver fibrosis evaluation is an important issue in chronic hepatitis B infection, and may be assessed using transient elastography (Fibroscan) or with blood markers. We compared the value of Fibroscan with that of a panel of routine serum markers. Materials and methods We recruited 278 chronic hepatitis B patients who underwent Fibroscan and HBV DNA testing. Fibroscan assessments were made, and blood taken for the measurement of the gamma-glutamyl transferase (GGT) to platelet ratio (GPR), platelet count, aspartate aminotransaminase (AST), alanine aminotransaminase (ALT), international normalised ratio (INR), total cholesterol, trigylcerides, bilirubin, mean platelet volume (MPV), AST to platelet ratio index (APRI) and neutrophil to lymphocyte ratio...
June 12, 2018: British Journal of Biomedical Science
Chang-An Geng, Tong-Hua Yang, Xiao-Yan Huang, Jing Yang, Yun-Bao Ma, Tian-Ze Li, Xue-Mei Zhang, Ji-Jun Chen
ETHNOPHARMACOLOGICAL RELEVANCE: Artemisia capillaris (Yin-Chen) is a famous traditional Chinese medicine (TCM) for treating acute and chronic hepatitis in China. Enynes are one type of characteristic constituents in this herb, while their anti-hepatitis B virus (anti-HBV) properties have not been systemically investigated. AIM OF THE STUDY: This study is to reveal the active part of A. capillaris, and systemically investigate the enynes and their anti-HBV activity...
June 8, 2018: Journal of Ethnopharmacology
Aichao Shi, Xiaoping Zhang, Fang Xiao, Lin Zhu, Weiming Yan, Meifang Han, Xiaoping Luo, Tao Chen, Qin Ning
HBV surface antigen (HBsAg) reduction is well observed in chronic hepatitis B (CHB) patients treated with pegylated interferon-alpha-2a (Peg-IFNα). However, the mechanism of HBsAg suppression has not been fully elucidated. Twenty-seven of 55 Entecavir-treated CHB e antigen positive patients were switched to Peg-IFNα treatment (Group A) whereas 28 patients continued entecavir treatment (Group B). The percentage or absolute number of CD56bright /CD56dim NK cells, expression of receptors and cytokines were evaluated by flow cytometry for 48 weeks and correlated with treatment efficacy...
June 11, 2018: Journal of Viral Hepatitis
Vadim G Krivoshapkin, Sergei I Semenov, Svetlana S Maximova, Nadegda N Tihonova, Anna I Sivtseva, Snegana S Sleptsova
OBJECTIVE: Inrtroduction: The epidemiological situation for hepatitis D has changed significantly. Reduced population authors infection due to a sharp decline in hospitalizations from Central Asia regions, the Caucasus and Moldova, which are known to be endemic for hepatitis D. Currently, the incidence of chronic hepatitis D (HGD) in Russia is 1%, while in the countries of Central Asia, and in particular in Turkmenistan, the share of HGD among chronic viral hepatitis is 8%. The aim of research was to establish the clinical features, depending on the activity of the replication of hepatitis viruses B and D...
2018: Wiadomości Lekarskie: Organ Polskiego Towarzystwa Lekarskiego
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"